Thrombosis associated with the use of recombinant activated factor VII: profiling two events

Recombinant factor VIIa (rFVIIa; NovoSeven®, NovoNordisk) has been used for the treatment of bleeding episodes in hemophilia A and B patients with inhibitors for over a decade. Its utility as a hemostatic agent has extended beyond these initial indications and is increasingly used in trauma, surgery and platelet disorders when conventional measures are inadequate for the control of active or anticipated bleeding. On account of its ability to initiate coagulation, the potential to induce thrombotic events has been a concern. Various reviews on its safety profile has indicated the contrary and it has shown resilience as a very safe agent with an incidence of serious adverse events associated with its use being less than 1%. . . .